基于PvMSP9线性B细胞表位的合成肽免疫原性研究
本研究以间日疟原虫裂殖子表面蛋白9(PvMSP-9)的线性B细胞表位PvMSP9E795-A808为基础,在BALB/c小鼠中评估合成肽的免疫原性。结果显示所有肽构建物均具免疫原性并可诱导特异性IgG,含T细胞表位的构建物抗体应答更强、可识别天然蛋白。
要点
- PvMSP9E795-A808表位在小鼠中具高度免疫原性
- 含T细胞表位构建物诱导更高抗体滴度并识别天然蛋白
- 支持CD4 T细胞表位增强亚单位疫苗体液应答
核心结论
- PvMSP9E795-A808在小鼠中高度免疫原性,值得进一步评估其作为疫苗靶点的价值。
- 含T细胞表位的合成肽可增强抗体应答并识别天然蛋白。
研究设计与样本
- 在BALB/c小鼠中评估合成肽免疫原性,肽包括RII、pLRII和TTRII。
- 免疫应答通过ELISA、FLUOROSPOT和间接免疫荧光评价。
主要发现
- 所有测试的肽构建物均具免疫原性,诱导不同水平的特异性IgG,以IgG1和IgG2为主。
- 含T细胞表位的pLRII或TTRII诱导更有效抗体应答,抗体滴度更高并能识别天然蛋白。
- TTRII免疫诱导的IFN-γ分泌SFC频率与PvMSP9-Nt重组蛋白报道结果相当。
临床怎么用
- 提示PvMSP9E795-A808可作为间日疟疫苗候选表位进一步研究。
- 亚单位疫苗设计可考虑引入CD4 T细胞表位以增强体液免疫。
局限性
- 研究仅在BALB/c小鼠中进行,尚未在人体验证。
- 原文未报告具体样本量、抗体滴度数值及统计学参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasmodium vivax Merozoite Surface Protein-9 (PvMSP-9) is a malaria vaccine candidate naturally immunogenic in humans and able to induce high antibody titers in animals when delivered as a recombinant protein. Recently, we identified the sequence EAAPENAEPVHENA (PvMSP9E795-A808) as the main linear B-cell epitope in naturally exposed individuals. However, the potential of PvMSP9E795-A808 as an immunogen in experimental animal models remained unexplored. Here we assess the immunogenicity of PvMSP9E795-A808 using synthetic peptides. The peptides tested in BALB/c mice include two repeats of the sequence EAAPENAEPVHENA tested alone (peptide RII), or linked to an autologous (PvMSP9 peptide pL; pLRII) or heterologous (p2 tetanus toxin universal T cell epitope; TTRII) T cell epitope. Immune responses were evaluated by ELISA, FLUOROSPOT, and indirect immunofluorescence. We show that all of the peptide constructs tested were immunogenic eliciting specific IgG antibodies at different levels, with a prevalence of IgG1 and IgG2. Animals immunized with synthetic peptides containing T cell epitopes (pLRII or TTRII) had more efficient antibody responses that resulted in higher antibody titers able to recognize the native protein by immunofluorescence. Relevantly, the frequency of IFN-γ secreting SFC elicited by immunization with TTRII synthetic peptide was comparable to that reported to the PvMSP9-Nt recombinant protein. Taken together, our study indicates that PvMSP9E795-A808 is highly immunogenic in mice and further studies to evaluate its value as promising vaccine target are warranted. Moreover, our study supports the critical role of CD4 T cell epitopes to enhance humoral responses induced by subunit based vaccines.
引用
- Rodrigues-da-Silva RN, Correa-Moreira D, Soares IF, et al. Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9. Vaccine. 2018. PMID: 30509693. doi:10.1016/j.vaccine.2018.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。